ReviewCardiorenal medicine2026
Multimodal Detection of Subclinical Cardiovascular Disease in Chronic Kidney Disease.
Review in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is the leading cause of mortality among individuals with chronic kidney disease (CKD) and is driven by chronic inflammation, oxidative stress, vascular calcification, accumulation of uremic toxins, ventricular remodeling, and microvascular dysfunction. Subclinical CVD is highly prevalent in CKD and often remains unrecognized until advanced stages, contributing to delayed intervention and increased mortality. SUMMARY: Early detection of subclinical CVD in CKD is critical to prevent disease progression and reduce adverse outcomes. Advances in noninvasive imaging modalities - including echocardiography, coronary computed tomography angiography, coronary artery calcium (CAC) scoring, and cardiac magnetic resonance imaging - enable sensitive identification of early cardiac and vascular abnormalities. In parallel, circulating and urinary biomarkers such as C-reactive protein, high-sensitivity troponin (hsT), N-terminal pro-brain natriuretic peptide, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), fibroblast growth factor-23, and urine albumin-to-creatinine ratio provide insight into underlying pathophysiological mechanisms and support risk stratification and personalized management. KEY MESSAGES: Subclinical CVD is common yet underdiagnosed in CKD, necessitating improved screening strategies. Integration of advanced imaging techniques with biomarker profiling offers a promising approach for early detection and individualized care. Continued innovation and implementation of these tools are essential to closing the cardiovascular mortality gap in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.